Form 4: Zomedica director granted 1.82M SARs

Director Robert Cohen received 1,823,107 stock appreciation rights, exercisable from Nov. 16, 2026 and expiring Nov. 16, 2035 at a $0.10 base price.

Summary

• Director Robert Cohen was awarded 1,823,107 Stock Appreciation Rights (SARs) on 11/17/2025.
• The SARs have a base/exercise price of $0.10 per share.
• The SARs become exercisable on 11/16/2026 and expire on 11/16/2035.
• Post-transaction beneficial ownership of derivative securities: 1,823,107 SARs, held directly.
• No transactions in non-derivative (common) securities were reported.
• Transaction code “A” denotes an award/grant; price of derivative security at grant reported as $0.

Sentiment

Score: 5

Explanation: Neutral overall: routine director equity award aligning incentives, offset by potential dilution from 1.82M underlying shares.

Positives

• Equity-based award aligns director incentives with long-term shareholder value through a 10-year term (expiring 11/16/2035).
• One-year wait to first exercisability (11/16/2026) supports retention and longer-term focus.
• No cash outlay at grant; price of derivative security reported as $0 at the time of award.

Negatives

• Potential dilution if SARs are settled in shares, with up to 1,823,107 underlying common shares.
• Low base price ($0.10) increases the likelihood of value transfer to the holder if the stock trades above the base price.
• Creates incremental equity overhang concentrated with a single director.

Future Outlook

No forward-looking statements or guidance provided; this is an insider equity award disclosure.

Industry Context

Equity awards to directors via SARs/options are common among small-cap life sciences and animal-health companies to align incentives and conserve cash; a 10-year term with first exercisability after one year is typical for U.S.-listed firms.

Comparison to Industry Standards

• Ten-year equity award terms are standard across many U.S.-listed companies; animal-health peers like Zoetis (ZTS) and IDEXX (IDXX) often grant long-dated equity, though larger peers more frequently use RSUs for directors.
• A one-year wait before exercisability is consistent with typical vesting/exercise practices for director grants.
• Use of SARs (rather than RSUs) is more common in smaller-cap issuers seeking leverage to share price performance and cash conservation.

Related Party Transactions

• Grant of 1,823,107 stock appreciation rights to Director Robert Cohen on 11/17/2025 at a $0.10 base price, expiring 11/16/2035.

Stakeholder Impact

• Shareholders: potential dilution up to 1,823,107 shares if SARs are settled in equity.
• Directors/Management: increased alignment with share price performance through SARs.
• Employees: no direct impact disclosed; reflects continued use of equity-based compensation.
• Creditors: no immediate cash impact from the award.

Next Steps

• SARs become exercisable on 11/16/2026.
• SARs expire on 11/16/2035 if not exercised.

Key Dates

Keywords

Zomedica, ZOMDF, stock appreciation right, SAR grant, Form 4, insider transaction, director compensation, equity award, derivative securities, beneficial ownership, animal health